Sernova Corp. (TSE:SVA) Forecasted to Earn FY2025 Earnings of ($0.10) Per Share

Sernova Corp. (TSE:SVA) – Stock analysts at Ventum Cap Mkts issued their FY2025 earnings per share (EPS) estimates for shares of Sernova in a research report issued to clients and investors on Tuesday, September 17th. Ventum Cap Mkts analyst S. Quenneville expects that the company will post earnings of ($0.10) per share for the year. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.

A number of other analysts have also recently issued reports on the company. Leede Financial decreased their target price on Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating for the company in a report on Friday, September 13th. Ventum Financial decreased their target price on Sernova from C$3.00 to C$2.50 and set a “buy” rating for the company in a report on Friday, September 13th.

Sernova Stock Down 5.8 %

Shares of TSE:SVA opened at C$0.25 on Thursday. The company has a debt-to-equity ratio of 16.55, a quick ratio of 18.11 and a current ratio of 0.62. Sernova has a 1 year low of C$0.20 and a 1 year high of C$0.83. The stock has a market capitalization of C$79.48 million, a P/E ratio of -1.88 and a beta of 1.38. The stock has a 50-day simple moving average of C$0.26 and a 200-day simple moving average of C$0.36.

Sernova (TSE:SVA) last issued its earnings results on Monday, September 16th. The company reported C($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.03) by C$0.01.

Insider Buying and Selling

In related news, Director Steven Sangha sold 930,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total transaction of C$223,200.00. In the last ninety days, insiders have purchased 379,600 shares of company stock valued at $97,671. Corporate insiders own 12.98% of the company’s stock.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.